Market Overview - The A-share market opened lower but closed higher, with the Shenzhen Component Index rising over 1% [1] - The total trading volume in the Shanghai and Shenzhen markets was 1.85 trillion, a decrease of 903 billion compared to the previous trading day [1][5] - More than 4,300 stocks in the market experienced gains, indicating a broad-based rally [1] Sector Performance - The lithium battery industry chain saw significant gains, with multiple stocks hitting the daily limit, including Rongjie Co., Ltd. with four consecutive limit-ups and Shida Shenghua with two consecutive limit-ups [1] - The pharmaceutical sector also performed well, with Keta Bio hitting the daily limit and several other stocks showing strong upward momentum [1] - The chemical sector was active, with stocks like Suli Co., Ltd. and Luban Chemical hitting the daily limit [1] Declines - In contrast, several stocks in the green energy sector experienced declines, with Liaoning Energy hitting the limit down and other companies like Jieneng Wind Power and Hunan Development also facing significant drops [2] Closing Statistics - At the close, the Shanghai Composite Index rose by 0.63%, the Shenzhen Component Index increased by 1.13%, and the ChiNext Index gained 0.71% [3][4]

Market Overview - A-shares opened lower but rose throughout the day, with major indices collectively increasing and turning positive [1] - The A-share market saw a surge in the non-ferrous metals, pharmaceutical biology, and basic chemicals sectors, leading to a wave of stocks hitting the daily limit [1][4] A-share Performance - By the end of the morning session, the Shanghai Composite Index rose by 0.26%, the Shenzhen Component Index by 0.93%, the ChiNext Index by 0.83%, and the Sci-Tech Innovation Index by 1.08% [4] - The non-ferrous metals sector led the gains with an increase of 2.6%, with multiple stocks hitting the daily limit, including Shenzhen New Star, Haixing Co., Rongjie Co., Yunnan Zhiye, and others [4][5] Pharmaceutical Sector - The pharmaceutical biology sector also performed well, with stocks like Hotgen Biotech, Yinuo Si, Shutaishen, and Huana Pharmaceutical seeing increases of over 10% [6][7] - Notable stocks in this sector included Hotgen Biotech with a rise of 14.70% and Shutaishen with an increase of 11.50% [7] Basic Chemicals Sector - The basic chemicals sector experienced significant gains, with stocks such as Keta Biotech and Shandong Haihua hitting the daily limit [8][9] - Keta Biotech saw a remarkable increase of 19.99%, while other stocks in the sector also posted gains around 10% [9] New Listings - A new stock, Puan Medical, was listed today, with its price surging over 170% at one point during the session [11][12] - Puan Medical specializes in diabetes care and related medical devices, with a projected increase in global insulin pen needle sales from 8.81 billion units in 2022 to 9.97 billion units by 2024 [12] Hong Kong Market - The Hong Kong market experienced narrow fluctuations, with China Longgong's stock surging over 20% during the morning session [13][15] - China Longgong reported a total revenue of RMB 11.215 billion for the year 2025, reflecting a year-on-year growth of 9.81%, with significant contributions from electric loaders and export products [15][16]

Market Overview - The A-share market opened lower but rebounded, with all three major indices turning positive. The half-day trading volume in the Shanghai and Shenzhen markets was 1.14 trillion, a decrease of 84.3 billion compared to the previous trading day [1]. Stock Performance - Over 3,700 stocks in the market rose, indicating a broad-based rally [2]. Sector Highlights - The lithium mining sector saw significant gains, with Rongjie Co. achieving a four-day consecutive rise, while Jiangte Electric, Jinyuan Co., and Shengxin Lithium Energy hit the daily limit [3]. - The pharmaceutical sector also performed strongly, with Keta Bio reaching the daily limit, Meinuohua achieving five gains in six days, and Wanbangde recording three gains in four days. Lianhuan Pharmaceutical and Shuanglu Pharmaceutical also hit the daily limit [3]. - The chemical sector was active, with Sully Co., Lubai Chemical, and Jinzheng all reaching the daily limit [3]. Declines - In contrast, several stocks in the green energy sector experienced declines, with Liaoning Energy hitting the daily limit down, and both Jieneng Wind Power and Haili Wind Power seeing significant drops [4]. Closing Summary - By the end of the trading session, the Shanghai Composite Index rose by 0.26%, the Shenzhen Component Index increased by 0.93%, and the ChiNext Index was up by 0.83% [5].

Group 1 - The A-share market for innovative drugs is experiencing significant gains, with companies like Meinohua, Wanbangde, and Lianhuan Pharmaceutical hitting the 10% daily limit, while Ketaobiotech saw a remarkable 20% increase [1] - As of March 21, 2026, the total value of China's innovative drug outbound business development (BD) contracts has reached $57.1 billion, with an upfront payment of $3.3 billion and a total of 53 contracts, representing 41% of the total for 2025, surpassing the entire year of 2024 [1] - Several leading innovative drug companies have confirmed a turning point in profitability, with Hengrui Medicine projecting that nearly 60% of its revenue will come from innovative drugs by 2025, and a growth forecast of over 30% for 2026 [1] Group 2 - The 2026 government work report has significantly elevated the strategic position of the biopharmaceutical industry, placing it alongside integrated circuits and aerospace as a new pillar industry for the nation [1] - Notable companies such as Nuocheng Jianhua, Yunding Xinyao, and Jingtai Holdings are expected to achieve profitability in 2025 [1]

证券代码：300858 证券简称：科拓生物 公告编号：2026-004 北京科拓恒通生物技术股份有限公司 第三届董事会第十六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1、北京科拓恒通生物技术股份有限公司（以下简称"公司"）第三届董事会 第十六次会议通知于 2026 年 2 月 6 日以邮件通知方式向各位董事发出，同时列 明了会议的召开时间、内容和方式。 2、本次会议于 2026 年 2 月 10 日以通讯表决方式进行。 4、本次董事会由董事长孙天松女士召集和主持，公司高级管理人员列席了 本次董事会。 5、本次会议的召集、召开和表决程序符合《中华人民共和国公司法》等法 律法规和《北京科拓恒通生物技术股份有限公司章程》的有关规定，会议合法、 有效。 二、董事会会议审议情况 经全体与会董事认真审议，形成决议如下： （一） 审议通过《关于 2026 年度日常关联交易预计的议案》 董事会认为，公司 2026 年度日常关联交易预计系公司日常经营所需，属于 正常的商业交易行为。 本议案已经公司独立董事专门会议及董事会审计委员会审 ...

证券代码：300858 证券简称：科拓生物 公告编号：2026-005 北京科拓恒通生物技术股份有限公司 关于 2026 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 北京科拓恒通生物技术股份有限公司（以下简称"公司"）根据日常经营的 实际需要，预计 2026 年度与公司首席科学家张和平教授发生日常关联交易总金 额不超过人民币 150.00 万元（税前）。 根据《深圳证券交易所创业板股票上市规则》和《公司章程》等相关规定， 该议案在董事会审批权限范围内，无须提交公司股东会审议。 （二）2026 年度预计日常关联交易类别和金额 单位：万元 | 关联交易类别 | 关联人 | 关联交易内容 | 关联交易 | 2026 年度预计 | | 截至披露日 | 2025 | 年度发 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 定价原则 | 关联交易金额 | | 已发生金额 | | 生金额 | | 接受关联人提 ...

证券代码：300858 证券简称：科拓生物 公告编号：2026-002 | | | 本次减持前持有股份 | | 本次减持后持有股份 | | | --- | --- | --- | --- | --- | --- | | 股东名称 | 股份性质 | 股数（股） | 占公司总 | 股数（股） | 占公司总 | | | | | 股本比例 | | 股本比例 | 北京科拓恒通生物技术股份有限公司 关于特定股东减持计划期限届满的公告 公司股东张列兵保证向本公司提供的信息内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 北京科拓恒通生物技术股份有限公司（以下简称"公司"）于2025年10月12 日披露了《关于特定股东减持股份预披露公告》（公告编号：2025-041）。特定 股东张列兵计划在减持公告披露之日起3个交易日后的3个月内以集中竞价、大宗 交易的方式拟减持公司股份数量不超过5,000,000股，即不超过公司股份总数的 1.8976%。 公司于近日收到特定股东张列兵出具的《关于股份减持计划期限届满的告知 函》，截至2026年1月15日，上述 ...

Core Viewpoint - The company, Kato Bio (300858.SZ), has successfully passed the high-tech enterprise certification again and has received the "High-tech Enterprise Certificate" issued by the Beijing Municipal Science and Technology Commission, Beijing Municipal Finance Bureau, and the State Taxation Administration of Beijing [1] Group 1 - The company has been recognized as a high-tech enterprise, indicating its commitment to innovation and technology development [1] - The certification is a significant achievement that may enhance the company's reputation and credibility in the industry [1] - Receiving this certificate can potentially lead to various benefits, including tax incentives and increased funding opportunities [1]

证券代码：300858 证券简称：科拓生物 公告编号：2026-003 北京科拓恒通生物技术股份有限公司 关于公司通过高新技术企业重新认定的公告 | 企业名称 | 证书编号 | | 发证时间 | | | 有效期 | | --- | --- | --- | --- | --- | --- | --- | | 北京科拓恒通生物技术股份有限公司 | GR202511004436 | 2025 | 年 12 | 月 | 日 2 | 三年 | 本次高新技术企业认定为公司原高新技术企业证书有效期满后所进行的重 新认定，根据《中华人民共和国企业所得税法》以及国家对高新技术企业的相关 税收规定，公司自本次通过高新技术企业重新认定后连续三年（2025-2027 年） 可继续享受高新技术企业的相关税收优惠政策，按 15%的税率缴纳企业所得税。 上述税收优惠政策不影响公司目前适用的企业所得税税率，不会对公司经营 业绩产生重大影响。 特此公告。 北京科拓恒通生物技术股份有限公司 董事会 2026 年 1 月 19 日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 北京科拓恒通生物技 ...

Core Viewpoint - On January 19, a total of 17 listed companies had their restricted shares unlocked, with a total market value of approximately 8.181 billion yuan [1]. Summary by Category Restricted Share Unlocking - The following companies had restricted shares unlocked: - Vanadium Titanium Co., Ltd. (Stock Code: 000629) - 4.0126 million shares from equity incentive [1] - Guodian NARI Technology Co., Ltd. (Stock Code: 600406) - 11.883 million shares from equity incentive [1] - Huayi Group Co., Ltd. (Stock Code: 600623) - 356,100 shares from equity incentive [1] - Western Securities Co., Ltd. (Stock Code: 002673) - 360 million shares from A-share issuance to original shareholders [1] - Chang Aluminum Co., Ltd. (Stock Code: 002160) - 237 million shares from A-share issuance to legal persons [1] - Hikvision Digital Technology Co., Ltd. (Stock Code: 002415) - 29.2208 million shares from equity incentive [1] - Jieshun Technology Co., Ltd. (Stock Code: 002609) - 258,100 shares from equity incentive [1] - Yaoji Technology Co., Ltd. (Stock Code: 002605) - 975,000 shares from equity incentive [1] - Subote Co., Ltd. (Stock Code: 603916) - 629,000 shares from equity incentive [1] - Yipin Hong Co., Ltd. (Stock Code: 300723) - 150,000 shares from equity incentive [1] - Shandong Fiberglass Group Co., Ltd. (Stock Code: 605006) - 112,200 shares from equity incentive [1] - Keta Bio-Pharmaceutical Co., Ltd. (Stock Code: 300858) - 2.0053 million shares from A-share issuance to legal persons [1] - Xinlei Co., Ltd. (Stock Code: 301317) - 112 million shares from pre-issuance restrictions [1] - Zhiwei Intelligent Co., Ltd. (Stock Code: 001339) - 293,500 shares from equity incentive [1] - Demingli Co., Ltd. (Stock Code: 001309) - 247,500 shares from equity incentive [1] - Jiuzhou Yigui Co., Ltd. (Stock Code: 688485) - 600,000 shares [1] - Yingfang Software Co., Ltd. (Stock Code: 688435) - 36.3174 million shares [1]